Person-Environment Fit for Persons With Dementia

May 9, 2024 updated by: Elizabeth K Rhodus

Improving Person-Environment Fit of Community-Residing Older Adults With Dementia

This trial will assess feasibility of a non-pharmacological intervention for persons living with Alzheimer's disease and related dementias (ADRD) to improve behavioral and psychiatric symptoms of dementia and functional performance.

Using a two-arm, prospective randomized controlled trial, 38 dyads (person with ADRD and caregiver) will complete an 8-week telehealth occupational therapy intervention provided via Zoom with caregivers and persons with dementia or receive an active control with 8 telehealth sessions to discuss publicly available caregiver education with a non-clinical research assistant.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

76

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • Recruiting
        • University of Kentucky
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria: Participants with Dementia

  • Men or women aged 60-99, inclusive.
  • Living at home in the community with one primary caregiver.
  • Diagnosis or probably diagnosis of dementia (confirmed by Clinical Dementia Rating Scale score of 1.0+)
  • If on psychotropic medication, they are at a point where dosage and treatment are stabilized for the duration of the study.
  • Functional sensory abilities with or without aids (hearing, vision, smell, touch, taste)
  • Caregiver report of challenges related to behaviors within 4 weeks of study enrollment.
  • Caregiver willing to participate throughout duration of study.
  • Contact with University of Kentucky Alzheimer's Disease Research Center or Kentucky Neuroscience Institute medical provider within 12 months of study recruitment.

Inclusion Criteria: Caregiver for Participants with Dementia

  • Men or women aged 21-99, inclusive.
  • Willingness to participate in study and implement recommended data collection tools.
  • English speaking, able to read and write.
  • Ability to retrieve and send mail.

Exclusion Criteria: Participants with Dementia

  • Unstable medical conditions within one month prior to screening visit such as poorly controlled blood pressure, diabetes, current cancer diagnosis, or breathing problems, etc.
  • Wheelchair or bed bound.
  • Residence in skilled nursing facility or facility-based care.
  • Caregiver report of physically violent behaviors.
  • Initiation of antipsychotic medication within 4 weeks prior to screening or unpredictable use of such medications
  • Diagnosis of profound or total sensory altering disorders including macular degeneration, legal blindness, total deafness, severe peripheral neuropathy, anosmia.
  • Major depression in past 12 months (DSM-IV criteria), major mental illness such as schizophrenia, bipolar disorder, personality disorders, or recent (in past 12 months) alcohol or substance abuse.
  • Major infection within 4 weeks prior to the Baseline Visit.

Exclusion Criteria: Caregiver for Participant with Dementia:

• Diagnosis of mild cognitive impairment or dementia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Harmony at HOME
Participants in this group will receive the Harmony at HOME intervention.
The Harmony at HOME (Help Online Modifying the Environment) intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
Active Comparator: National Institute on Aging Program
Participants in this group will receive the National Institute on Aging education.
Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging "Home Safety and Alzheimer's Disease" webpage.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in patient performance as measured by Canadian Occupational Performance Measure (COPM)
Time Frame: 13weeks (baseline, post-intervention, follow up)
Criterion-referenced interview of patient performance with caregiver The COPM is a reliable and validated measure of performance in primary daily activities (self-care, leisure, productivity) with dyad-caregiver rated of performance and satisfaction. Scores are determined on a likert scale of 1-10 with 1 being lowest and 10 indicating highest of the topic of the question.
13weeks (baseline, post-intervention, follow up)
Caregiver satisfaction of patient performance [Feasibility]
Time Frame: 13 weeks (baseline, post intervention, follow up)
The primary outcome analysis is the feasibility of implementation as measured by caregiver satisfaction. The Canadian Occupational Performance Measure will measure caregiver satisfaction of patient performance, high scores indicate higher levels of satisfaction. Range 0-10.
13 weeks (baseline, post intervention, follow up)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Zarit Caregiver Burden Scale
Time Frame: 13 weeks (baseline, post intervention, follow up)
22-item survey, caregiver rates self-perceived level of burden on 5-point Likert scale. The social context of the person with ADRD will be described through analysis of caregiver demographics and rate of caregiver burden measured. Higher scores indicate greater burden. Range of 0-88 points. A score of 17 or more was considered high burden.
13 weeks (baseline, post intervention, follow up)
Neuropsychiatric Inventory Questionnaire (NPI-Q)
Time Frame: 13 weeks (baseline, post intervention, follow up)
The NPI-Q is commonly used as an assessment of behavioral and psychiatric symptoms of dementia in older adults diagnosed with mild cognitive impairment or dementia, internationally, with high reliability and validity. Assessment includes 12 behavioral and psychiatric domains which are rated by caregiver as present or absent (yes/no). Caregivers further rate severity of present behavioral domains. The severity score is summed to yield a total as a measure of BPSD burden. Higher scores indicate higher levels of behavior symptom severity and/or distress. Range 0-36
13 weeks (baseline, post intervention, follow up)
Functional Behavior Profile (FBP)
Time Frame: 13 weeks (baseline, post intervention, follow up)
Criterion-referenced survey completed by caregiver. The FBP has been established as a reliable and valid measure of task performance, social interaction, and problem solving with adults with ADRD. Item responses range from 0 to 4, with higher scores indicating better performance (maximum score 108).
13 weeks (baseline, post intervention, follow up)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Home Occupational Environment Assessment (HOEA)
Time Frame: 1 time (baseline)
35-item survey completed by caregiver regarding home environment. Allows the caregiver to systematically assess the home environment including accessibility, sanitation, food storage, safety, and sensorial stimulation. Scores range 0-105 with higher scores indicating worse outcomes.
1 time (baseline)
Adult Sensory Profile (ASP)
Time Frame: 1 time (baseline)
Norm-referenced, 60-item survey completed by caregiver. The caregiver will complete the Adult Sensory Profile as proxy for person with ADRD. This is a valid and reliable 60-question assessment to determine sensory simulation preference and neurological ability for processing sensory simulation. This assessment is not based on a range of scores but normative values. Results can be more than or less than normative values.
1 time (baseline)
Clinical Dementia Rating Scale (CDR-SUM)
Time Frame: 1 time (baseline)
The Clinical Dementia Rating (CDR) sum of boxes, a valid and reliable measure, will determine severity of cognitive impairment. Six cognitive domains are assessed in CDR (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care) with feedback from patient performance and caregiver result, and results are scored by a trained professional. Range 0-18, higher scores indicate higher levels of cognitive impairment.
1 time (baseline)
Digital Biomarker of psychophysiological response to environment: heart rate variability
Time Frame: Device worn by patient for 7 consecutive days
Empatica wearable wrist device Assessment of stress-related biomarkers will measure heart rate variability in beats per minute.
Device worn by patient for 7 consecutive days
Digital Biomarker of psychophysiological response to environment: electrodermal activity
Time Frame: Device worn by patient for 7 consecutive days
Empatica wearable wrist device Assessment of stress-related biomarkers will measure electrical conductance at the surface of the skin. Skin conductance is measured in units of microsiemens, with normal human EDA ranging from 1 to 20 microsiemens.
Device worn by patient for 7 consecutive days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Elizabeth Rhodus, PhD, University of Kentucky

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2023

Primary Completion (Estimated)

August 30, 2025

Study Completion (Estimated)

June 15, 2026

Study Registration Dates

First Submitted

December 27, 2022

First Submitted That Met QC Criteria

February 1, 2023

First Posted (Actual)

February 10, 2023

Study Record Updates

Last Update Posted (Actual)

May 10, 2024

Last Update Submitted That Met QC Criteria

May 9, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Harmony at HOME

3
Subscribe